Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Johns Hopkins Medicine

Status and phase

Enrolling

Phase 2

Conditions

Pancreatic Ductal Adenocarcinoma

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Treatments

Drug: Pembrolizumab

Drug: Defactinib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03727880

IRB00182490 (Other Identifier)

J18140

Details and patient eligibility

About

This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.

Enrollment

36 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years.
Has pancreatic ductal adenocarcinoma
Has resectable disease at the time of diagnosis
Has not received any systemic therapy for pancreatic ductal adenocarcinoma
Has stage ≤ IIb disease at time of diagnosis and enrollment
Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200
ECOG performance status 0 or 1
Patient must have adequate organ function defined by the study-specified laboratory tests.
Must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document.

Exclusion criteria

Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer.

Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
Has received prior therapy with FAK inhibitor.
Woman who are pregnant or breastfeeding.
Have received a live vaccine or live-attenuated vaccine within 30 days prior to study drug.
Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug.
History or current use of immunosuppressive medications within 7 days prior to study medications.
Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years.
Has active autoimmune disease that has required systemic treatment in the past 2 years.
Has a history of (non-infectious) pneumonitis/interstitial lung disease or current pneumonitis.
Has an active infection requiring systemic therapy.
Infection with HIV or hepatitis B or C.
Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Known allergy or hypersensitivity to the study drugs.
Received any growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration.
Has history of any organ transplant, including corneal transplants.